This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Subscribe To Our Newsletter & Stay Updated
